3731-59-7

Basic information

• Product Name: Moroxydine
• Synonyms: TIMTEC-BB SBB003847;n-(aminoiminomethyl)-4-morpholinecarboximidamide;MOROXYDINUM;moroxydine;1-(1-morpholinoformimidoyl)guanidine;Moroxydine (base and/or unspecified salts);N-[amino(imino)methyl]morpholine-4-carboximidamide hydrochloride;ABOB
• CAS NO: 3731-59-7
• Molecular Formula: C₆H₁₃N₅O
• Molecular Weight: 171.2
• EINECS: 223-093-1
• Product Categories: Building Blocks;Chemical Synthesis;Guanidines;Nitrogen Compounds;Organic Building Blocks
• Mol File: 3731-59-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 211-214 °C(lit.)
• Boiling Point: 327 °C at 760 mmHg
• Flash Point: 151.6 °C
• Appearance: /
• Density: 1.51 g/cm³
• Vapor Pressure: 0.000207mmHg at 25°C
• Refractive Index: 1.661
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 13.01±0.10(Predicted)
• Merck: 13,6295
• CAS DataBase Reference: Moroxydine(CAS DataBase Reference)
• NIST Chemistry Reference: Moroxydine(3731-59-7)
• EPA Substance Registry System: Moroxydine(3731-59-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 3731-59-7(Hazardous Substances Data)

Usage

Uses

antiviral

Therapeutic Function

Antiviral

InChI:InChI=1/C6H13N5O/c7-5(8)10-6(9)11-1-3-12-4-2-11/h1-4H2,(H5,7,8,9,10)

Upstream product

• 3160-91-6 moroxydine hydrochloride 
• 110-91-8 morpholine 
• 127099-85-8 N-Cyanoguanidine 
• 10024-89-2 morpholin hydrochloride 

Downstream Products

• 58248-25-2 N-[(benzyl-thiocarbamoyl)-carbamimidoyl]-morpholine-4-carboximidic acid amide 
• 58248-20-7 N-(phenylcarbamoyl-carbamimidoyl)-morpholine-4-carboximidic acid amide 
• 58248-19-4 N-(cyclohexylcarbamoyl-carbamimidoyl)-morpholine-4-carboximidic acid amide 
• 36092-20-3 N-(5-oxo-4,4-diphenyl-4,5-dihydro-1H-imidazol-2-yl)-morpholine-4-carboximidic acid amide 
• 66709-75-9 2-Amino-4-morpholino-6-alkyl-1,3,5-Triazin 
• 66709-79-3 2-Amino-4-morpholino-6-alkyl-1,3,5-Triazin 
• 140161-23-5 Morpholin-4- 
• 2045-25-2 4-morpholino-1,3,5-triazin-2-amine 
• 1430334-09-0 4-benzyl-6-(morpholin-4-yl)-1,3,5-triazin-2-amine 
• 7537-63-5 4-amino-6-(morpholin-4-yl)-N-phenyl-1,3,5-triazine-2-carboxamide 
• 871332-26-2 ethyl {4-[{[2-amino-4-(morpholin-4-yl)-1,3,5-triazin-6-yl]methyl}amino]benzoyl}-L-glutamate 
• 871332-18-2 4-({[2-amino-4-(morpholin-4-yl)-1,3,5-triazin-6-yl]methyl}amino)benzoic acid 
• 21868-41-7 2-amino-4-morpholino-6-chloromethyl-1,3,5-triazine 
• 201229-58-5 N-(4-Amino-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-4-chloro-2-mercapto-5-methyl-benzenesulfonamide 

Relevant articles and documents

N-(2-guanidino-ethylimino)-morpholine antigen based on thiotriazinone structure restrictiveness, antibody and application

The present invention discloses a N-(2-guanidino-ethylimino)-morpholine hapten based on thiotriazinone structure restrictiveness, an artificial antigen, an antibody and an application. The structure of the N-(2-guanidino-ethylimino)-morpholine hapten is represented by a formula I shown in the description, wherein R is -H and -CH3. The N-(2-guanidino-ethylimino)-morpholine artificial antigen and antibody are prepared base on the hapten, and the artificial antigen and antibody have high detection efficiency and simple operation to N-(2-guanidino-ethylimino)-morpholine, and can be used in enzyme-linked immunosorbent assay rapid detection of the N-(2-guanidino-ethylimino)-morpholine; and the antigen and the antibody have a simple synthetic process, lower costs, and good application prospects.

Regioselective synthesis of pyrimido[1,2-a][1,3,5]triazin-6-ones via reaction of 1-(6-oxo-1,6-dihydropyrimidin-2-yl)guanidines with triethylorthoacetate: Observation of an unexpected rearrangement

A novel thermal rearrangement, involving pyrimidine ring opening and subsequent ring closure leading to recyclization of the system, was identified in the reaction of (6-oxo-1,6-dihydropyrimidin-2-yl)guanidines 3 (where NR 1R2 = NH2, NH alkyl, NH aralkyl, NHCH 2Ph(R)) with triethyl orthoacetate, affording 4-substituted-2-methyl- 6H-pyrimido[1,2-a][1,3,5]triazin-6-ones 6 and their ring opened products. However, no such rearrangement was observed with (6-oxo-1,6-dihydropyrimidin-2- yl)guanidines 3 bearing a tertiary amino or anilino substituent (i.e. where NR1R2 = N(CH3)2, indoline, morpholino, NHAr). As expected, 2-substituted-4-methyl-6H-pyrimido[1,2-a][1,3,5] triazin-6-ones 4 were obtained as the final products. Experimental structural determination and theoretical studies were carried out to get an understanding of the observed thermal rearrangement. In addition, an attempt to obtain similar pyrimido[1,2-a][1,3,5]triazin-6-ones using N,N-dimethylacetamide dimethyl acetal (DMA-DMA) as one carbon inserting synthon had furnished triazine ring annulated product 14 bearing N,N-dimethyl enamino substituent at position 4 as a result of further reaction with a second molecule of DMA-DMA.

3-deoxyglucosone and skin

The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.